编号：2018004 证券代码：002022 证券简称：科华生物 上海科华生物工程股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|--------------------------------------------------|-----------------------------------------------------------------------| | | | | | 投资者关系活 | | 特定对象调研 □分析师会议 | | 动类别 | □ | 媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 □ 现场参观 □其他: 电话会议 | | | 参与单位名称 及人员姓名 | 详见附件名单 | | | 时间 | 2018 年 5 月 23 | 日下午 3 点 | | 地点 | 公司会议室 | | | 上市公司接待 人员姓名 | | 总裁丁伟、董事会秘书王锡林、证券事务代表宋钰锟 | | 投资者关系活 | 交流纪要： | | | 动主要内容介 绍 | | 本次电话会议过程中，首先由公司总裁丁伟先生就公 ...

Group 1: Company Strategy and Performance - The core strategy since 2017 is "product-centric and market-oriented," with 2018's operations aligning with this strategy [2] - Significant acquisitions in molecular diagnostics, including Suzhou Tianlong and Xi'an Tianlong, enhance product and technology positioning [2] - The biochemical business remains a major cash flow source, with a focus on optimizing resource allocation and integrating marketing teams [3] Group 2: Financial Highlights - Channel acquisitions contribute approximately 20% to total revenue, with net profit around 10% [4] - The company has obtained over 30 certifications for the Hitachi 008 system, which is expected to become a new growth point [3] Group 3: Future Outlook and Goals - The company aims to achieve industry-leading levels in key business areas over the next three to five years, with a focus on maintaining strategic execution [5] - The second phase of the equity incentive plan is expected to enhance company cohesion and support strategic deployment [3] Group 4: Market Trends and Challenges - The molecular diagnostics sector is identified as a high-growth area, with ongoing collaborations expected to yield significant results [4] - The company is cautiously exploring bundled procurement models, emphasizing long-term partnerships with hospitals [5]

Group 1: Company Strategy and Performance - The core strategy since 2017 is "product-centric and market-oriented" [2] - The acquisition of Tianlong is significant for the company's layout in molecular diagnostics, with operational improvements noted [2] - The company has established Shandong Kehua to enhance channel and product sales after several acquisitions in southern regions [2] Group 2: Financial Performance and Projections - Tianlong's integration is expected to contribute positively to the company's performance in 2018, with revenue growth compared to the previous year [3] - The company aims to achieve industry-leading levels in key business areas over the next three years, exceeding the average industry growth rate [4] Group 3: Product Focus and Market Position - The biochemical business is a crucial cash flow source and a significant growth driver for the company [3] - The company plans to launch new products through its channels, ensuring both short-term and long-term growth [3] Group 4: Market Trends and Business Model - The company is cautiously exploring the bundled procurement model, focusing on long-term partnerships with hospitals [4] - A dedicated team has been established to promote bundled services, aligning with national policies while maintaining selective engagement [4]

证券代码：002022 证券简称：科华生物 上海科华生物工程股份有限公司 投资者关系活动记录表 编号：2021001 | --- | --- | --- | --- | --- | |------------------------------------------------------------------------------------------|-----------------------------------------------|--------------------------------------------------------------------------------------|-------|------------------------------------| | 投资者关系活动类别 | □媒体采访 □业绩说明会 \n□新闻发布会 □路演活动 | 特定对象调研 □分析师会议 | | | | | □现场参观 | | | | | | □其他 : 电话会议 | | | | | 参与单位名称及人员姓名 | 国盛证券 国泰基金 | 李顺帆；汇添富基金 胡静霆； ...

证券代码：002022 证券简称：科华生物 编号：2020002 | --- | --- | --- | --- | |---------------------------|----------------------------------------------------------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | □ 特定对象调研 □ | | 媒体采访 | | 特定对象来 | □ 分析师会议 □ | √ | 业绩说明会 | | 访目的 | □ 新闻发布会 | □ | 现场参观 | | | □ 其他（请文字说明） | | | | 来访者单位名称 及人员姓名 | 通过"全景·路演天下"（ 司 2020 | | http://rs.p5w.net ）参加公 ...

证券代码：002022 证券简称：*ST 科华 债券代码：128124 债券简称：科华转债 上海科华生物工程股份有限公司 投资者关系活动记录表 编号：2022001 | --- | --- | --- | |-----------------------|---------------------------------------------|------------------------------------------------------------| | | | | | 投资者关系活动 类别 | □ 特定对象调研 □ 媒体采访 | □ 分析师会议 √ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 其他 | （请文字说明其他活动内容） | | 参与单位名称及 | □ 通过全景网"投资者关系互动平台"（ | http://ir.p5w.net | | 人员姓名 | 加公司 2021 | 年度网上业绩说明会的投资者 | | 时间 | 2022 年 5 月 25 日 | (周三) 下午 15:00-17:00 | | 地点 | 公司通过全景网"投资者关系互动平台" ...

上海科华生物工程股份有限公司 2022 年第三季度报告 证券代码：002022 证券简称：*ST科华 公告编号：2022-096 债券代码：128124 债券简称：科华转债 上海科华生物工程股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大 遗漏，并承担个别和连带的法律责任。 2.公司负责人马志超先生、主管会计工作负责人罗芳女士及会计机构负责人(会计主管人员)俞蕾女士声明：保证季度报告 中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 676,494,983.81 ...

上海科华生物工程股份有限公司 2022 年半年度报告全文 上海科华生物工程股份有限公司 2022 年半年度报告 2022-065 2022 年 08 月 1 上海科华生物工程股份有限公司 2022 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人周琴琴、主管会计工作负责人罗芳及会计机构负责人(会计主 管人员)俞蕾声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司控股子公司西安天隆科技有限公司、苏州天隆生物科技有限公司（以 下简称"天隆公司"）管理层，违反本公司对控股子公司管理规章制度的规定， 违反天隆公司《公司章程》规定，拒绝履行天隆公司董事会做出的决议，拒绝 配合本公司聘请的立信会计师事务所（特殊普通合伙）开展 2021 年度审计工 作，公司董事会基于谨慎考虑，审议将天隆公司自 2021 年 10 月 1 日起暂不纳 入公司合并报表。 本报告中涉及未来计划等前瞻性陈述，不构成公司对投资者的实质 ...

Financial Performance - The company's operating revenue for 2021 was CNY 4,268,011,808.72, representing a 2.71% increase compared to CNY 4,155,428,846.74 in 2020[20] - The net profit attributable to shareholders for 2021 was CNY 721,016,662.06, a 6.76% increase from CNY 675,356,413.28 in 2020[20] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 704,501,000.58, up 6.92% from CNY 658,928,540.60 in 2020[20] - Basic earnings per share for 2021 were CNY 1.4026, an increase of 5.10% from CNY 1.3345 in 2020[20] - The diluted earnings per share for 2021 were CNY 1.3641, a 3.54% increase from CNY 1.3175 in 2020[20] - The weighted average return on equity decreased to 20.87% from 24.76% in 2020, a decline of 3.89%[20] - Total assets at the end of 2021 were CNY 5,276,579,515.63, down 11.72% from CNY 5,977,153,474.43 at the end of 2020[20] - The net cash flow from operating activities decreased by 43.29% to CNY 775,342,174.21 from CNY 1,367,198,250.32 in 2020[20] - The company reported a total revenue of 1.5 billion RMB for the fiscal year 2021, representing a year-over-year growth of 15%[124] - The company reported a net profit of 300 million RMB, reflecting a 20% increase from the previous year[124] Market and Product Development - The company’s main business includes the R&D, production, and sales of in vitro diagnostic reagents and medical testing instruments, focusing on molecular, biochemical, and immunodiagnostics[34] - The global in vitro diagnostic market exceeded $111.7 billion in 2021, with a projected CAGR of 6.1% from 2017 to 2024, indicating strong growth potential in the industry[32] - The company has over 200 diagnostic reagents and instruments, with more than 80 products certified by the EU CE mark, and has exported products to over 30 countries and regions[34] - The company launched 21 reagent products and 2 instrument products that received medical device registration certificates during the reporting period, enhancing its product portfolio[44] - The Polaris ic6000 product was successfully launched, designed for large laboratories, contributing to the company's innovation in automated biochemical and immunological analysis systems[42] - The company aims to launch three new products in the next quarter, which are anticipated to contribute an additional 100 million RMB in revenue[126] - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share within the next two years[125] Research and Development - The company has over 100 ongoing research projects and has obtained 260 CFDA registration certificates and more than 50 invention patents[38] - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[119] - Investment in R&D for new technologies increased by 25%, totaling 200 million RMB, focusing on immunological and molecular diagnostics[124] - The company will continue to invest in R&D, particularly in molecular and immunological fields, to develop new products and improve existing ones[97] Challenges and Risks - The company faces risks related to the ongoing COVID-19 pandemic, which may impact sales of diagnostic products[98] - Regulatory changes in the in vitro diagnostic industry pose a risk to the company's operations and compliance[99] - The company faces increasing challenges in the in vitro diagnostic industry due to healthcare cost control measures, which may accelerate industry concentration and require manufacturers to strengthen their marketing capabilities[101] - The company is currently involved in a significant arbitration case, with the Shanghai International Economic and Trade Arbitration Commission having formed a tribunal, but no ruling has been made yet, making the impact on profits uncertain[102] - The company's stock has been placed under delisting risk warning due to management violations at its subsidiaries, leading to an "unable to express opinion" audit report for the 2021 fiscal year[102] Governance and Compliance - The company has established a governance structure that includes a board of directors, supervisory board, and various committees to ensure compliance with laws and regulations[107] - The company has implemented a transparent performance evaluation and incentive mechanism for its directors and senior management to ensure the achievement of strategic goals[109] - The company has committed to improving its information disclosure practices, ensuring timely and accurate communication with investors[110] - The company maintains complete independence from its major shareholders in terms of business operations, personnel, assets, institutions, and finance[111] - The company has established independent departments for various functions, including sales, R&D, procurement, and finance, ensuring operational independence[112] Employee and Operational Management - The total number of employees at the end of the reporting period was 1,485, with 926 in the parent company and 559 in major subsidiaries[137] - The company has a training plan that includes diverse training programs for different employee levels, aimed at enhancing organizational performance[140] - The company has established a performance-oriented compensation system that aligns employee contributions with organizational goals[139] - The company’s internal control and compliance management received positive feedback from the audit committee, indicating effective governance[136] Dividend and Profit Distribution - The company plans to distribute a cash dividend of CNY 0.65 per 10 shares (including tax) to all shareholders[6] - The total distributable profit for the period was 759,082,903.41 CNY, with the cash dividend representing 100% of the profit distribution[144] - The company did not propose any stock dividends or capital reserve transfers during the reporting period[146] Financial Management and Investments - The company has established a new supply chain management structure to optimize processes and reduce costs, enhancing operational efficiency[46] - The company reported a significant decrease in investment amounting to CNY 7.14 million, a decline of 71.27% compared to the previous year's CNY 24.85 million[77] - The company raised a total of CNY 738 million through the issuance of convertible bonds, with a net amount of CNY 718.53 million after deducting issuance costs[85] Social Responsibility - A 22-member volunteer team was formed to assist in COVID-19 testing efforts, demonstrating the company's commitment to social responsibility[166]

上海科华生物工程股份有限公司 2022 年第一季度报告全文 | 证券代码：002022 | 证券简称：科华生物 | 公告编号：2022-019 | | --- | --- | --- | | 债券代码：128124 | 债券简称：科华转债 | | 公司 2022 年 4 月 28 日召开第八届董事会第十六次会议，审议《关于控股子公司暂时失去控制且暂不纳入合并报表范围 的议案》，因天隆公司管理层违反本公司对控股子公司管理规章制度的规定，违反天隆公司《公司章程》规定，拒绝履行天 隆公司董事会做出的决议，拒绝配合本公司聘请的立信会计师事务所（特殊普通合伙）开展 2021 年度审计工作，公司目前 已经无法取得天隆公司的财务资料，无法掌握天隆公司的实际经营情况、资产状况及面临的风险等信息，公司对天隆公司的 管理控制无法得到天隆公司管理层的执行。公司董事会基于谨慎考虑，审议将天隆公司自 2021 年 10 月 1 日起暂不纳入公司 合并报表。 上海科华生物工程股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会 ...